Back to Search
Start Over
Advances in the Development of Phosphodiesterase-4 Inhibitors.
- Source :
-
Journal of medicinal chemistry [J Med Chem] 2020 Oct 08; Vol. 63 (19), pp. 10594-10617. Date of Electronic Publication: 2020 Jun 10. - Publication Year :
- 2020
-
Abstract
- Cyclic nucleotide phosphodiesterase 4 (PDE4) specifically hydrolyzes cyclic adenosine monophosphate (cAMP) and plays vital roles in biological processes such as cancer development. To date, PDE4 inhibitors have been widely studied as therapeutics for the treatment of various diseases such as chronic obstructive pulmonary disease, and many of them have progressed to clinical trials or have been approved as drugs. Herein, we review the advances in the development of PDE4 inhibitors in the past decade and will focus on their pharmacophores, PDE4 subfamily selectivity, and therapeutic potential. Hopefully, this analysis will lead to a strategy for development of novel therapeutics targeting PDE4.
- Subjects :
- Animals
Cyclic Nucleotide Phosphodiesterases, Type 4 chemistry
Cyclic Nucleotide Phosphodiesterases, Type 4 metabolism
Drug Discovery
Humans
Molecular Structure
Phosphodiesterase 4 Inhibitors chemistry
Phosphodiesterase 4 Inhibitors therapeutic use
Protein Conformation
Quinolones chemistry
Vomiting drug therapy
Drug Development
Phosphodiesterase 4 Inhibitors pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1520-4804
- Volume :
- 63
- Issue :
- 19
- Database :
- MEDLINE
- Journal :
- Journal of medicinal chemistry
- Publication Type :
- Academic Journal
- Accession number :
- 32255344
- Full Text :
- https://doi.org/10.1021/acs.jmedchem.9b02170